Biogen Idec, Inc. (BIIB) Misses Q4 EPS by 6c; Guides FY13 EPS Below Views
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.78 +1.13%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.40, $0.06 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.38 billion.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
